Rafivirumab
Appearance
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | rabies virus glycoprotein |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C6462H9954N1718O2036S46 |
Molar mass | 145761.46 g·mol−1 |
![]() ![]() |
Rafivirumab (CR57) is a monoclonal antibody for the prophylaxis of rabies.[1][2][3]
References
- ^ "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). World Health Organization.
- ^ Kramer RA, Marissen WE, Goudsmit J, Visser TJ, Clijsters-Van der Horst M, Bakker AQ, et al. (July 2005). "The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries". European Journal of Immunology. 35 (7): 2131–45. doi:10.1002/eji.200526134. PMID 15971273.
- ^ Franka R, Carson WC, Ellison JA, Taylor ST, Smith TG, Kuzmina NA, et al. (September 2017). "In Vivo Efficacy of a Cocktail of Human Monoclonal Antibodies (CL184) Against Diverse North American Bat Rabies Virus Variants". Tropical Medicine and Infectious Disease. 2 (3): 48. doi:10.3390/tropicalmed2030048. PMC 6082099. PMID 30270905.